Ildiko ☕️ retweeted
Vedolizumab or ustekinumab for pediatric UC? In 108 patients under 21 (Stanford), 1-year steroid-free remission in UC/IBD-U was 61% on vedolizumab vs 32% on ustekinumab; in Crohn disease, 64% vs 67%. Trials still needed. #IBD #PedsIBD
doi.org/10.1002/jpn3.70198
Ildiko ☕️ retweeted
Excited to share our new paper in @JCI_insight
How does genetic risk shape CD4 T cell recognition in #IBD?
We linked HLA-DRB1 genotype to >3.1 million memory CD4+ TCRβ sequences in Crohn’s disease, ulcerative colitis and controls.
Ildiko ☕️ retweeted
Ultraprocessed Grains and Risk of Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology Study
Narula, et al.
📕 doi.org/10.14309/ajg.0000000…
Serum proteomics in paediatric inflammatory bowel disease from a case–control study: biomarker discovery and ulcerative colitis–Crohn's disease differentiation - eBioMedicine thelancet.com/journals/ebiom…
Ildiko ☕️ retweeted
Not every day you see an odds ratio of 50 (for interleukin-10 autoantibodies and a common HLA allele).
~80% of patients with inflammatory bowel disease (IBD) have this HLA allele
These individuals (~3.5% of IBD) may benefit from B cell depletion (such as achieved via CAR T).
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE…
Can Food Actually Be Medicine? These Doctors Say Yes nytimes.com/2026/04/10/dinin… via @NYTimes
3
374
Ildiko ☕️ retweeted
@virgosvs has the most interesting dataset in all of healthcare. 3M+ high definition endoscopy videos.
we're using it to build AI that predicts treatment outcomes and solve diseases mediated by the gut:
IBD
EoE
celiac
obesity
liver disease
colorectal cancer
pancreatic cancer
Ildiko ☕️ retweeted
Our research article on the gut virome, where we talked about how phage mediates bacterial metabolism and hence intestinal inflammation, was selected by the journal as a Featured Article. What an honor!
Virome enterotype dictates inflammation
Gut mucosal virome enterotypes influence intestinal inflammation w/Entero-2 predominant in Crohn’s disease & proinflammatory in mice. E2 enriched in phage that ↑B. theta sphingosine production & alters inflammation
cell.com/cell-host-microbe/a…
At least some of this has been known for a while and is a reason we need much more robust investigation in every individual diagnosed with IBD. Broad immune suppression is really a blunt instrument for a nuanced problem that I have always believed is resolvable.
New findings identify region-specific differences of inflammation in Crohn's across the GI tract in response to pathobionts
This could help leverage targeted delivery of therapies, and in specific IBD phenotypes
@jclinicalinvest
tinyurl.com/3ewhewmu
1
8
533
Ildiko ☕️ retweeted
Question for #IBD friends/practitioners: Randomly, calprotectin numbers jumped to 2000+ in Oct and Jan. However, no significant clinical symptoms. Now a calprotectin of 21 at the end of March.
No changes in symptoms/treatment/diet/etc. What could cause this?!
Ildiko ☕️ retweeted
I have an amazing idea for this! Please reach out if you have an interest in Crohn's, and want to apply for this to see if it can support a super cool postdoctoral fellowship project in my lab.
Postdocs: We’ll be accepting applications April 13-June 1 for the Rainin Visionary Scientist Award. Grants of $300K each over two years will support three early career scientists conducting innovative biomedical research relevant to IBD. krfoundation.org/news/health…
This is still happening today with conflicts of interest, both undisclosed and disclosed (but essentially ignored by everyone). I look forward to the retractions in 2075.
Retraction—Today, we retract an unsigned 1977 commentary suggesting talc powder containing asbestos was not harmful. The Lancet was informed that the author had undisclosed competing interests and breached publication ethics. /4
ALT Social media card dated 25.03.2026. The text reads, “Retraction—Today, we retract an unsigned 1977 commentary on the safety of asbestos in talcum powder. We thank David Rosner and Gerald Markowitz for their rigorous investigation and alerting The Lancet that the commentary was written by a paid consultant of Johnson & Johnson—representing undeclared competing interest and a clear breach of publication ethics. Our editorial processes have evolved significantly since 1977 to improve transparency, ethical standards, and scientific integrity. In our view, had our editors at the time known of this situation, they would not have published this piece. Therefore, we are now retracting it.”
Ildiko ☕️ retweeted
Reviewers said, this sounds like a fishing expedition.
I said, indeed, but we've got really great nets and there are tons of fish.
We aren't out to prove a single hypothesis. We've set out on a discovery journey to investigate what we don't understand
Amen. This is the way. We have been telling ourselves there is a cost to “unnecessary tests” but the real cost is in lack of intellectual curiosity, lack of investigation, lack of accuracy in diagnoses, lack of prevention, and an epidemic of chronic disease.
Ildiko ☕️ retweeted
We're searching for the next Director of the Duchossois Family Institute at UChicago
The most exciting leadership role in microbiome science right now: lead faculty, cutting-edge cores, an FDA-approved facility for microbiome therapeutics
Apply here: apply.interfolio.com/182203
Ildiko ☕️ retweeted
There has been a recent shift in pediatric IBD care to repeat colonoscopy 1 year post diagnosis to ensure deep tissue level remission. Even if asymptomatic and fecal cal normalized. Has anyone seen flares occur after these surveillance scopes? cleanouts do impact microbiome
I know this is going to be very controversial but we need to consider the possibility that maybe, just maybe, colonoscopy prep, which is massively disruptive to the microbiome and significantly increases calprotectin, is itself a risk for, or exacerbates, flares. I have one rule in IBD: never mess with whatever is working.
46M w UC, was in remission on IFX+AZA x5 yrs, off all tx & managing w diet x2 yrs
🔦Outpt colon: Mayo 2
2 wks later: 20+ bloody BM/d, wt loss. Alb 3, CRP 37, FCP 2670, C diff -
Admitted 🏥, no response day 3 of IVCS. AXR w mild colon distention
What is your rescue therapy?
38%IFX + premedications
13%High dose TOFA
42%High dose UPA
6%Colectomy
219 votes • Final resultsThis. I said this during covid when preprints made progress incredibly fast. Anything else in IBD is a waste of time and energy and huge disservice to patients.
I currently have three papers in review at "high impact" journals.
One of them has been sitting there for two years. In that time my daughter was born and learned how to walk, but apparently publishing a PDF was still not possible for me. For another one, after four months in review the editor told me they cannot find a second reviewer and asked me to suggest more reviewers. A third one sent me a message in 2026 saying the PDF I uploaded was larger than 10 MB and that I should please reupload everything to make the file smaller.
All of this just to eventually pay between 7,000 and 12,000 USD per paper so someone can officially approve that the science we do is "legitimate". Reminder: not a single reviewer will be compensated here.
I still don't understand how we as scientists can collectively be so smart when doing science and still tolerate a system like this when it comes to sharing our findings. We should move to preprints plus open review, whether human or AI, asap. So frustrated about it.
I'd suggest sharing your work on bioRxiv or medRxiv, reading and reviewing preprints when you can, and highlighting good research, especially if it is still a preprint. Try platforms like ResearchHub (that pay for peer review) and experiment with AI based reviewers for faster feedback.
Instead I read this as a proposed "revolutionary" measure:
2
9
1,270
Ildiko ☕️ retweeted
⚠️Childhood antibiotic use is a risk factor for developing inflammatory bowel disease, with about 42% higher risk. The risk for ulcerative colitis was 23% and for Crohn disease was 59%. This was true despite controlling for infections.
academic.oup.com/ibdjournal/…
